FWM
PCVX icon

Focused Wealth Management’s Vaxcyte PCVX Stock Holding History

Focused Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9
Closed -$432 – 1126
2022
Q4 		$432 Buy
+9
New +$353 ﹤0.01% 964

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Focused Wealth Management's PCVX Position: Q1 2023 in Review

Focused Wealth Management sold out of Vaxcyte (PCVX) in Q1 2023, closing a stake of 9 shares — an estimated $432 sold.

Focused Wealth Management first reported a position in PCVX in Q4 2022 and held it in 1 quarter. The position peaked at $432 in Q4 2022. 187 funds tracked by Wall St. Rank hold PCVX as of Q1 2023.

  • Focused Wealth Management reported no remaining Vaxcyte position as of Q1 2023 after selling out during the quarter.
  • Focused Wealth Management sold 9 Vaxcyte shares in Q1 2023, an estimated $432.
  • Focused Wealth Management first reported a position in Vaxcyte in Q4 2022 and held it in 1 quarter.
  • Focused Wealth Management's Vaxcyte position peaked at $432 in Q4 2022.
  • 187 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2023.

Based on Focused Wealth Management's 13F filing for Q1 2023, filed 13 Apr 2023.